Cardiology








Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.



_1_2_Square.jpg)


A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.

The novel self-expanding bioprosthetic ACURATE neo valve did not demonstrate noninferiority to the currently available CoreValve Evolute valve in patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), according to the SCOPE* II trial.

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.



